Ultra-low-dose same-target combinations control drug resistance across stages

A five-drug ultra-low-dose same-target combination against EGFR delayed resistant outgrowth versus single-agent EGFR inhibitors at ~50% growth inhibition, and 8–14 inhibitors showed no detectable resistance within the timeframe.

• Why it matters: Drug resistance limits long-term cancer control, and inhibitory strength alone may not predict whether resistant outgrowth will emerge during EGFR-targeted therapy.
• What they did: In EGFR-driven cancer models, researchers tested ultra-low-dose same-target combinations using multiple EGFR inhibitors with minimal single-agent activity, comparing resistance emergence after similar growth inhibition (~50%) and varying inhibitor counts up to 8–14.
• The result: Single-agent EGFR inhibitors generated resistant outgrowth, while the five-drug ULDC delayed resistance emergence; increasing inhibitor number further delayed it, and ULDC-derived resistant cells showed markedly greater reversibility after drug withdrawal.

AI summary of the abstract · may contain errors · not medical advice · read the paper.